Riyadh - Sharikat Mubasher: Jamjoom Pharma, one of the fastest-growing pharmaceutical companies in the Middle East and Africa, signed a strategic memorandum of understanding (MoU) with Magrabi Health Group to enhance Ophthalmology services in Saudi Arabia.

The partnership aims to enhance cooperation in ophthalmology through medical training, health awareness, and the advancement of innovative therapeutic solutions, according to the official statement.

Both entities aim to deliver an integrated model that improves the quality of healthcare provided to ophthalmology patients across Saudi Arabia and the broader region.

Tarek Hosni, CEO of Jamjoom Pharma, stated that the partnership marks a vital strategic step toward reinforcing the company’s role in supporting the healthcare sector through collaboration with a leading provider of eye care services. “Through this agreement, we aim to develop high-quality programs that raise health awareness and deliver innovative therapeutic solutions tailored to patient needs,” he said.

The MoU focuses on launching several joint initiatives, developing specialized training programs for ophthalmologists and other healthcare practitioners, in addition to organizing scientific workshops and conferences to upskill medical personnel and ensure they remain aligned with the latest global practices in diagnosis and treatment.

For his part, Mutasim Alireza, CEO and Board Member at Magrabi Health Group, commented: “We are proud to collaborate with Jamjoom Pharma, an initiative that reflects our ongoing commitment to elevating ophthalmology services by investing in medical education and modern technologies. This partnership will allow us to expand our services and reach a broader demographic, with a steadfast focus on quality of care and patient safety."